Book Review

Angell Marcia (1996), Science on Trial: The Clash of Medical Evidence and the Law in the Breast Implant Case. New York: W.W. Norton & Co.

Avorn Jerry (2004), Powerful Medicines: The Benefits, Risks, and Costs of Prescription Drugs. New York: Knopf.

Chau Ian and Cunningham David (2002), “Cyclooxygenase Inhibition in Cancer: A Blind Alley or a New Therapeutic Reality?” New England Journal of Medicine, 346 (14), 1085–1087.

DiMasi Joseph A. and Paquette Cherie (2004), “The Economics of Follow-On Drug Research and Development: Trends in Entry Rates and Timing of Development,” Pharmacoeconomics, 22 (2), 1–14.

Goozner Merrill (2004), The $800 Million Pill: The Truth Behind the Cost of New Drugs. Berkeley: University of California Press.

Hankey Graeme J. and Eikelboom John W. (2003), “Cyclooxygenase-2 Inhibitors: Are They Really Atherothrombotic, and If Not, Why Not?” Stroke, 34 (November), 2736–40.

Holden Constance (2003), “Future Brightening for Depression Treatments,” Science, (October 31), 810–13.

Jenkins John K. and Seligman Paul J. (2005), “Analysis and Recommendations for Agency Action Regarding Non-Steroidal Anti-Inflammatory Drugs and Cardiovascular Risk,” FDA memorandum, Center for Drug Evaluation and Research, Office of New 310 Book Reviews Drugs, (April 6), (accessed May 1, 2005), [available at http://www.fda.gov/cder/drug/infopage/COX2/NSAIDdecisionMemo.pdf].

Langreth Robert (1998), “Drug Marketing Drives Many Clinical Trials,” The Wall Street Journal, (November 16).

Lee Thomas H. (2004), “Perspective: ‘Me-Too’ Products: Friend or Foe?” New England Journal of Medicine, 350 (3), 211–12.

Lichtenberg Frank R. and Philipson Tomas J. (2003), “The Dual Effects of Intellectual Property Regulations: Within- and Between-Patent Competition in the U.S. Pharmaceuticals Industry,” Journal of Law and Economics, 45 (October), 643–72.

Shephard James , Cobbe Stuart M. , Ford Ian , Isles Christopher G. , Lorimer A. Ross , Macfarlane Peter W. , McKillop James H. , and Packard Christopher J. , for the West of Scotland Coronary Prevention Study Group (1995), “Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia,” New England Journal of Medicine, 333 (20), 1301–1307.

Wilkes Michael (2005), “Review of Angell's The Truth About the Drug Companies: How They Deceive Us and What to Do About It, and Kassirer's On the Take: How Medicine's Complicity with Big Business Can Endanger Your Health,” Journal of the American Medical Association, 293 (24), 3107–3108.